Literature DB >> 12069172

Massive and selective delivery of lipid-coated cationic lipoplexes of oligonucleotides targeted in vivo to hepatic endothelial cells.

Martin Bartsch1, Alida H Weeke-Klimp, Dirk K F Meijer, Gerrit L Scherphof, Jan A A M Kamps.   

Abstract

PURPOSE: Previously we reported on massive uptake of liposomes surface-modified with negatively charged aconitylated albumin (AcoHSA) by liver sinusoidal endothelial cells (EC) in vivo. In the present work we applied this principle for the in vivo delivery of antisense oligonucleotides (ODN) to these cells.
METHODS: Anti ICAM-1 ODN was complexed with the cationic lipid DOTAP and the complex was coated by an excess of neutral lipids including a lipid-anchored poly(ethylene glycol). Aco-HSA was coupled to the coated cationic lipoplexes (CCLs). Plasma disappearance, organ and intrahepatic distribution of Aco-HSA modified CCLs were determined in rats, using [3H]-cholesteryl oleyl ether and 32P-labeled ODN as markers.
RESULTS: The Aco-HSA coupled CCLs were <160 nm in size, contained 1.03+/-0.35 nmol ODN and 54+/-18 microg Aco-HSA per micromol total lipid. These CCLs were rapidly eliminated from plasma, about 60% the injected dose of 3H- or 32P-label being recovered in the liver after 30 min. Within the liver, the EC accounted for two thirds of total liver uptake. Control non-targeted CCLs were eliminated very slowly: after 30 min still >90% of the particles was in the blood.
CONCLUSIONS: Our results demonstrate efficient targeting of antisense ODN to EC in vivo, employing plasma-stable coated cationic lipoplexes, surface modified with negatively charged albumin. 40% of the injected ODN was delivered to the target cells within 30 min.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12069172     DOI: 10.1023/a:1015318415705

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  24 in total

Review 1.  Clinical studies of antisense therapy in cancer.

Authors:  A R Yuen; B I Sikic
Journal:  Front Biosci       Date:  2000-06-01

2.  Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells.

Authors:  J A Kamps; H W Morselt; P J Swart; D K Meijer; G L Scherphof
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

3.  Lactosylated low density lipoprotein: a potential carrier for the site-specific delivery of drugs to Kupffer cells.

Authors:  M K Bijsterbosch; G J Ziere; T J Van Berkel
Journal:  Mol Pharmacol       Date:  1989-09       Impact factor: 4.436

4.  Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors.

Authors:  E A Biessen; H Vietsch; J Kuiper; M K Bijsterbosch; T J Berkel
Journal:  Mol Pharmacol       Date:  1998-02       Impact factor: 4.436

5.  Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms.

Authors:  M Y Chiang; H Chan; M A Zounes; S M Freier; W F Lima; C F Bennett
Journal:  J Biol Chem       Date:  1991-09-25       Impact factor: 5.157

Review 6.  Lipoplexes and tumours. A review.

Authors:  C R Dass; M A Burton
Journal:  J Pharm Pharmacol       Date:  1999-07       Impact factor: 3.765

7.  A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1.

Authors:  D D Stuart; G Y Kao; T M Allen
Journal:  Cancer Gene Ther       Date:  2000-03       Impact factor: 5.987

8.  Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.

Authors:  C F Bennett; M Y Chiang; H Chan; J E Shoemaker; C K Mirabelli
Journal:  Mol Pharmacol       Date:  1992-06       Impact factor: 4.436

9.  Preparation and characterization of conjugates of (modified) human serum albumin and liposomes: drug carriers with an intrinsic anti-HIV activity.

Authors:  J A Kamps; P J Swart; H W Morselt; R Pauwels; M P De Béthune; E De Clercq; D K Meijer; G L Scherphof
Journal:  Biochim Biophys Acta       Date:  1996-01-31

10.  Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells.

Authors:  Y W Huang; J A Richardson; E S Vitetta
Journal:  Cancer Res       Date:  1995-02-01       Impact factor: 12.701

View more
  5 in total

1.  A peptide-based vector for efficient gene transfer in vitro and in vivo.

Authors:  Taavi Lehto; Oscar E Simonson; Imre Mäger; Kariem Ezzat; Helena Sork; Dana-Maria Copolovici; Joana R Viola; Eman M Zaghloul; Per Lundin; Pedro M D Moreno; Maarja Mäe; Nikita Oskolkov; Julia Suhorutšenko; C I Edvard Smith; Samir E L Andaloussi
Journal:  Mol Ther       Date:  2011-02-22       Impact factor: 11.454

2.  Effect of Nanoparticle Synthetic Conditions on Ligand Coating Integrity and Subsequent Nano-Biointeractions.

Authors:  Jessica C Hsu; Yu Du; Arjun Sengupta; Yuxi C Dong; Katherine J Mossburg; Mathilde Bouché; Andrew D A Maidment; Aalim M Weljie; David P Cormode
Journal:  ACS Appl Mater Interfaces       Date:  2021-11-30       Impact factor: 9.229

3.  Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo.

Authors:  Samir E L Andaloussi; Taavi Lehto; Imre Mäger; Katri Rosenthal-Aizman; Iulian I Oprea; Oscar E Simonson; Helena Sork; Kariem Ezzat; Dana M Copolovici; Kaido Kurrikoff; Joana R Viola; Eman M Zaghloul; Rannar Sillard; Henrik J Johansson; Fatouma Said Hassane; Peter Guterstam; Julia Suhorutšenko; Pedro M D Moreno; Nikita Oskolkov; Jonas Hälldin; Ulf Tedebark; Andres Metspalu; Bernard Lebleu; Janne Lehtiö; C I Edvard Smith; Ulo Langel
Journal:  Nucleic Acids Res       Date:  2011-01-17       Impact factor: 16.971

4.  Mixing lipids to manipulate the ionization status of lipid nanoparticles for specific tissue targeting.

Authors:  Nour Shobaki; Yusuke Sato; Hideyoshi Harashima
Journal:  Int J Nanomedicine       Date:  2018-12-10

5.  Targeted delivery of hyaluronic acid nanomicelles to hepatic stellate cells in hepatic fibrosis rats.

Authors:  Wenhao Li; Chuchu Zhou; Yao Fu; Tijia Chen; Xing Liu; Zhirong Zhang; Tao Gong
Journal:  Acta Pharm Sin B       Date:  2019-07-18       Impact factor: 11.413

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.